Company achieves next major manufacturing milestone and advances global commercial strategy

公司实现下一个重大制造里程碑，推进全球商业战略

MENLO PARK, Calif., Jan. 8, 2024 /PRNewswire/ -- Antheia, the pharmaceutical ingredient manufacturer transforming essential medicine supply chains, today announced it has completed a successful validation campaign for its first product, thebaine, consisting of three consecutive full-scale fermentation runs at 116,000L to demonstrate process efficacy and consistency.

加利福尼亚州门洛帕克，2024年1月8日/PRNewswire/--改变基本药物供应链的药物成分制造商安西亚（Antheia）今天宣布，它已经成功完成了其第一种产品蒂巴因（thebaine）的验证活动，包括在116000升的温度下连续进行三次大规模发酵，以证明过程的有效性和一致性。

With the successful completion of this next manufacturing milestone, Antheia is rapidly advancing its commercial strategy to bring its Biosynthetic key starting materials (KSMs) and active pharmaceutical ingredients (APIs) to its leading global pharmaceutical customers..

随着下一个制造里程碑的成功完成，安西亚正在迅速推进其商业战略，将其生物合成关键原料（KSMs）和活性药物成分（API）带给其全球领先的制药客户。。

'Achieving process validation with a novel bio-based process in just one year is phenomenal and speaks volumes to the technical capabilities of our R&D and operations teams,' said Zack McGahey, COO of Antheia. 'As a company, we've demonstrated the viability and robustness of our platform at commercial scale and have established the foundation for the future of resilient pharmaceutical supply chains.'.

Antheia首席运营官扎克·麦加希（ZackMcGahey）说：“用一种新型的生物基工艺在一年内实现工艺验证是惊人的，这充分说明了我们研发和运营团队的技术能力。”作为一家公司，我们已经证明了我们平台在商业规模上的可行性和稳健性，并为未来的弹性药品供应链奠定了基础。”。

Completing a successful validation campaign in a short time frame is the result of Antheia's focused efforts to develop streamlined engineering solutions for its first product. The company will continue to invest in engineering and process optimizations to improve production throughput of thebaine, which will also bolster production and commercialization of Antheia's broader pipeline of KSMs and APIs in 2024 and beyond..

在短时间内完成成功的验证活动是Antheia致力于为其第一个产品开发简化的工程解决方案的结果。该公司将继续投资于工程和工艺优化，以提高蒂巴恩的生产吞吐量，这也将在2024年及以后促进安西亚更广泛的KSM和API管道的生产和商业化。。

'Achieving this next milestone of a successful validation campaign comes on the heels of a hallmark year of transformative growth for Antheia and is a testament to our team's unwavering dedication to ending drug shortages,' said Christina Smolke, PhD, CEO and co-founder of Antheia. 'We saw widespread industry commitment to our first products in 2023 and as we begin a new year, we are laser-focused on our commercial strategy to ship our first orders in 2024.'.

Antheia首席执行官兼联合创始人克里斯蒂娜·斯莫克（ChristinaSmolke）博士说：“在安西亚取得成功验证活动的下一个里程碑之后，安西亚迎来了标志性的变革性增长年份，这证明了我们团队坚定不移地致力于结束药物短缺。”我们在2023年看到了业界对我们第一批产品的广泛承诺，在我们开始新的一年之际，我们专注于我们的商业战略，以在2024年交付我们的第一批订单。”。

Antheia successfully achieved its first major commercial milestone in 2023 and unveiled the first products in a pipeline of 70+ pharmaceutical ingredients spanning seven critical therapeutic areas. The company also expanded its leadership team in 2023 with the addition of Richard Sherwin, SVP of Commercialization, Jesse Ahrendt, SVP of Quality Assurance and Regulatory Affairs, and industry veteran, John Nicols as Chair of Board of Directors.

Antheia于2023年成功实现了其第一个重大商业里程碑，并推出了跨越七个关键治疗领域的70多种药物成分的首批产品。2023年，公司还扩大了领导团队，增加了商业化高级副总裁理查德·舍温（Richard Sherwin）、质量保证和监管事务高级副总裁杰西·阿伦特（Jesse Ahrendt）和行业资深人士约翰·尼科尔斯（JohnNicols）担任董事会主席。

The company's continued success at full manufacturing scale further cements its platform as a next-gen solution for resilient, agile, and controlled pharmaceutical supply chains..

该公司在全面制造规模上的持续成功进一步巩固了其平台作为弹性，敏捷和受控制药供应链的下一代解决方案。。

About AntheiaAntheia is the next-generation pharmaceutical ingredient producer transforming essential medicine supply chains to end drug shortages. Using its novel whole-cell engineering approach, Antheia's biomanufacturing platform enables the reconstruction of biosynthetic pathways of unprecedented complexity in yeast cells and the scaling of fermentation processes to commercial levels.

关于AntheiaAntheia是下一代药物成分生产商，正在改造基本药物供应链以结束药物短缺。利用其新颖的全细胞工程方法，Antheia的生物制造平台能够重建酵母细胞中前所未有的复杂生物合成途径，并将发酵过程扩展到商业水平。

This highly flexible approach enables on-demand, agile, and resilient biomanufacturing of critical pharmaceutical ingredients, replacing legacy approaches that cannot support the needs of modern healthcare..

这种高度灵活的方法可以实现关键药物成分的按需，灵活和有弹性的生物制造，取代无法支持现代医疗保健需求的传统方法。。

Antheia's team of scientists and technologists is headquartered in Menlo Park, California. For more information, visit www.antheia.bio.

安西亚的科技团队总部位于加利福尼亚州门洛帕克。有关更多信息，请访问www.antheia.bio。

MEDIA CONTACT:Mission North for Antheia[email protected]

媒体联系人：Mission North for Antheia[受电子邮件保护]

SOURCE Antheia

SOURCE国歌